Gamida Cell Ltd. (NASDAQ:GMDA) Q4 2023 Earnings Conference Call March 27, 2024 8:30 AM ET

Company Participants

Mike Kuczkowski - Corporate Communications
Abbey Jenkins - President & Chief Executive Officer
Terry Coelho - Chief Financial Officer

Operator

Ladies and gentlemen, thank you for standing by. Welcome to Gamida Cell’s Conference Call for a Business Update in Fourth Quarter and Full Year 2023 Financial Results. My name is Darrel and I'll be your operator for today's call. Please be advised that this call is being recorded at Gamida Cell request.

Now I would like to introduce you to our conference host, Mike Kuczkowski of Gamida Cell Corporate Communications. Mike, please go ahead.

Mike Kuczkowski

Thank you, Darrel, and good morning, everyone. Welcome to today's call during which we will provide an update on the company and review our financial results for the fourth quarter and full year 2023.

Earlier this morning, we issued two press releases, one announcing the commencement of a restructuring process supported by Highbridge Capital Management and the other summarizing our financial results and providing a business update. Both press releases are available at our website, www.gamidacell.com. Please note, we will not be hosting a question-and-answer session on today's call.

Here with me on our call today are Abbey Jenkins, Gamida Cell’s President and Chief Executive Officer; and Terry Coelho, our Chief Financial Officer.

Before we begin, I want to remind everyone that during this call we may make forward looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements including those with respect to the curative therapeutic and commercial potential of OMISIRGE, Omidubicel-onlv Gamida Cell therapy candidate GD-201, the continued commercialization of and patient access to OMISIRGE, the financial runway of Gamida Cell. Gamida Cell's ability to complete a transaction supported by Highbridge pursuant to the restructuring support agreement, Gamida Cell's ability to secure the Israeli court's approval of the transaction. Gamida Cell's expectations regarding the delisting from NASDAQ and the timing of the completion of the restructuring proceedings and the state of Gamida Cell's workforce are subject to a number of risks, uncertainties and assumptions.

These risks, uncertainties and assumptions include those relating to clinical, scientific, regulatory and technical developments and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and as to the pursuit of the transactions contemplated under the RSA, the risk that no transaction may result.